国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (3): 236-238.doi: 10.3760/cma.j.issn.1673422X.2016.03.021

• 综述 • 上一篇    下一篇

膀胱癌的靶向药物治疗

 赵宁,张新伟   

  1. 300060 天津医科大学肿瘤医院生物治疗科 国家肿瘤临床医学研究中心 天津市“肿瘤防治”重点实验室 天津市肿瘤免疫与生物治疗重点实验室
  • 出版日期:2016-03-08 发布日期:2016-02-03
  • 通讯作者: 张新伟，Email: zhangxinwei@tjmuch.com E-mail: zhangxinwei@tjmuch.com
  • 基金资助:

     国家重点基础研究发展计划(973计划)（2012CB933304）； 国家自然科学基金（81402362）； 天津市自然科学基金（14JCYBJC27100）

Targeted drug therapy for bladder cancer

Zhao Ning, Zhang Xinwei   

  1. Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China
  • Online:2016-03-08 Published:2016-02-03
  • Contact: Zhang Xinwei, Email: zhangxinwei@tjmuch.com E-mail: zhangxinwei@tjmuch.com
  • Supported by:

    National Basic Research Program of China(973 Program)(2012CB933304); National Natural Science Foundation of China(81402362); Tianjin Municipal Natural Science Foundation (14JCYBJC27100)

PDF

2348

被引次数

1

摘要： 全身化疗是能够改善膀胱癌生存的主要治疗方法，然而疗效有限，因此靶向药物治疗在膀胱癌中的应用逐渐引人关注。目前针对膀胱癌的靶向药物包括贝伐珠单抗、西妥昔单抗、舒尼替尼、吉非替尼、依维莫司和程序性死亡受体1及其配体抑制剂，其为晚期膀胱癌的治疗提供了新的方向。

关键词: 膀胱肿瘤, 药物疗法

Abstract: Systemic chemotherapy is the main treatment which can improve the survival time of bladder cancer patients, though its efficacy is quite limited. The applications of targeted therapeutic drugs in bladder cancer has become more needed in clinic. At present the targeted drugs for bladder cancer include bevacizumab, cetuximab, sunitinib, gefitinib, everolimus and the inhibitor of programmed cell death-1 and its ligand, they provide a new direction for the treatment of advanced bladder cancer.

Key words: Urinary bladder neoplasms, Drug therapy